Swingeing cuts in social care that have left around 1.4 million older people in England unable to access the care and support they need.
News
Rinvoq bags FDA green light
In the SELECT programme, the oral JAK inhibitor met all primary and ranked secondary endpoints across a variety of rheumatoid arthritis patients.
Rozlytrek bags FDA approval
For the indication of ROS1-positive, metastatic non-small cell lung cancer (NSCLC).
£500,000 injected into ‘innovative’ AI online safety software
UK Meds has announced a partnership with Onfido to make buying prescription-only medicines online much safer.
Terlipressin hits phase III endpoint
CONFIRM is the largest-ever prospective study conducted in patients with hepatorenal syndrome type I.
Government to reconsider NHS Health Checks
The Health and Social Care Secretary has announced an evidence-based review into the service.
NHS toolkit launched for progressive neurological conditions
The NHS estimates there could be 2,500 fewer emergency admissions to hospital a year for patients with progressive neurological conditions.
‘Probe’ could help make prostate cancer surgery more accurate
The new project could ‘help surgeons to visualise tumours during keyhole surgery’.
Urgent medical delivery service set up in Brexit preparations
The £25 million contract to set up an express freight service aims to be completed in the next one to four days.
Evinacumab hits targets in late-stage cholesterol trial
On average patients entered the trial with LDL cholesterol levels of 255 mg/dL, despite treatment with other lipid-lowering therapies.
Taltz trumps Tremfya in plaque psoriasis study
The drug met the primary and all major secondary endpoints up to week 12 in the Phase IV IXORA-R study.
Marketer of the Year finalists share their experiences with the competition
Now in its 26th year, this prestigious competition has a long history of discovering and rewarding the very best healthcare marketers and last year was no exception.
Ebola ‘no longer incurable’
Two new drugs, mAb114 and REGN-EB3, have been found to dramatically cut mortality from Ebola.
AZ’ Calquence granted US Breakthrough Therapy Designation
The drug has been approved for chronic lymphocytic leukaemia.
Imbruvica bags EU expansion for two indications
The approval follows the Positive Opinion from the European Medicines Agency’s CHMP, and marks the fifth European approval in as many years.
